Page 2 - Eric Soyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAM's phagogram, first...

PHAXIAM Therapeutics announces high coverage performanceof its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAM’s phagogram, first CE-marked Phage Susceptibility Test ,...

PHAXIAM Therapeutics announces high coverage performanceof its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAM’s phagogram, first CE-marked Phage Susceptibility Test (PST), showed 98% response rate over 105 clinical S. aureus strains Lyon (France) et Cambridge (MA, US), October 9, 2023 at 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced a very high spectrum of activity of its anti-S. aureus (PP1493 and PP1815) phages against clinical ba

04.10.2023 - PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has ...